Düsseldorf, Germany– apr 17, 2025 – The European medical cannabis and industrial hemp group SYNBIOTIC SE and the venture capital company IRIS Capital Investment have entered into a strategic partnership. The French investment company will actively support SYNBIOTIC’s growth strategy. In a first phase, IRIS Capital Investment has decided and committed to subscribe for non-interest-bearing convertible bonds with a volume of up to EUR 2.4 million in several tranches of up to EUR 200,000 each. The issue of the first convertible bonds is scheduled to start at the end of April 2025.
DOWNLOAD SYNBIOTIC press release
